打破“数据孤岛”、加快AI制药，医药工业数智化转型将加快

Core Viewpoint - The implementation plan for the digital and intelligent transformation of the pharmaceutical industry aims for comprehensive coverage of intelligent transformation by 2030, enhancing innovation capabilities and improving the data system across the entire pharmaceutical industry chain [1][4]. Group 1: Current State and Challenges - The pharmaceutical industry in China is the world's largest exporter of active pharmaceutical ingredients and the second-largest market for drugs and medical devices, yet it faces challenges such as incomplete top-level design and insufficient proactive transformation capabilities [2]. - Key challenges in the digital transformation include data integration, specialized talent supply, and cross-sector collaboration mechanisms, with significant issues related to the "data island" phenomenon [2][3]. Group 2: Technological Integration and Safety - Digital transformation provides robust technical support for the entire lifecycle management of drugs, enabling precise control of production processes and real-time monitoring of quality data through digital means [3]. - The implementation of digital regulatory platforms has significantly improved the efficiency and accuracy of monitoring high-risk products like vaccines and blood products [3]. Group 3: Strategic Initiatives and Goals - The implementation plan outlines 14 key tasks across four areas to enhance the digital transformation capabilities of the pharmaceutical industry, focusing on integrating advanced technologies like artificial intelligence [4][5]. - Emphasis is placed on data element integration, encouraging collaboration among pharmaceutical companies, medical institutions, and research institutes to build high-quality data platforms [5]. - The plan aims to revise over 30 digital technology standards and develop guidelines for computerized system validation to ensure the deep integration of digital technologies with drug quality management [5].